ConductScience.org, home

Comparison · NCT02804750-eeae3e70

Group 1: Low-dose Group vs Group 2: High-dose Group: Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Group 1: Low-dose Group vs Group 2: High-dose Group: Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events. Trial comparisons, record NCT02804750-eeae3e70. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02804750-eeae3e70

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1760.06190.41wilson
Risk in group 20.3890.2030.614wilson
Risk difference, group 1 minus group 2-0.212-0.4650.0863newcombe hybrid score
Risk ratio, group 1 over group 20.4540.141.48log
Odds ratio, group 1 over group 20.3370.07031.61log
Number needed to treat, for one fewer participant with the outcome on Group 1: Low-dose Group than on Group 2: High-dose Group4.71from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Group 1: Low-dose Group100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. Period 3 was followed by a 4-week follow-up period.317OG000
Group 2Group 2: High-dose Group
250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. Period 4 was followed by a 4-week follow-up period.
718OG001

Outcome

Type
PRIMARY
Title
Percentage of Participants With One or More Severe (≥Grade 3) Adverse Events
Description
All treatment-emergent adverse events with Common Terminology Criteria for Adverse Events (CTCAE) ≥Grade 3 (severe) were recorded and summarized.
Time frame
Group 1: up to Week 16; Group 2: up to Week 20
Population
All enrolled participants who received at least 1 dose of study drug

Source ClinicalTrials.gov

Trial

Title
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
NCT number
NCT02804750
Phases
PHASE2
Conditions
Cushing's Syndrome
Interventions
CORT125134
Lead sponsor
Corcept Therapeutics
Results first posted
2019-09-25

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02804750-eeae3e70